The Netherlands has been a natural favourite for conducting clinical research with the Dutch healthcare system ranking among the best in Europe, the high level of education of investigators, large number of key opinion leaders, high quality standard of care (SOC) as well as the specialist centres in place that enables collection of reliable data. Yuva Oz and Inka Pawlitzky of SMS-oncology examine the contemporary landscape for clinical cancer drug research within its home base in the Netherlands.